Daria G. Husni

The new products aim to aid consumers with menopause and eye health-related issues.

This is the first biosimilar to Tysabri, an injection for adults with multiple sclerosis.

The patent grants Alterity 20 years of exclusivity over a new class of iron chaperone drug candidates.

The formulation will be used to mitigate emerging infectious diseases and public health emergencies.

The immunization, meant to protect infants aged six months or lower, is given to pregnant individuals at a gestation period of 32 to 36 weeks.

The assessment aims to determine whether valproate use in men could lead to neurodevelopmental disorders in their children.

A major grant from the Bill & Melinda Gates Foundation will bolster efforts to fight the global HIV/AIDS epidemic.

Novartis has completed its acquisition of biopharma company Chinook Therapeutics.

The guidance can help both applicants and manufacturers limit the mutagenic and carcinogenic potential of NDSRIs.

The new drug could be a powerful tool for patients suffering depressive symptoms after birth.

The investigational drug was developed to activate a novel uptake pathway, allowing antineoplastic drugs to combat solid tumors more successfully.

Lower levels of an active ingredient may result in unexpected pregnancies.

The nasal-spray drug can be used to reverse the effects of opioid overdose.

The program aims to aid submissions from external stakeholders and FDA staff.

The guidance document outlines recommendations to limit potential carcinogenic risk.

The damage to the facility, which produces 8% of US injectable drug consumption, should not significantly affect the current supply.

The framework is now expanded beyond COVID-19 vaccines and treatments.

The paper highlights the potential of AI in the medicinal product lifecycle and the approach that developers should take with it.

These recommendations will keep key antibiotics for respiratory infections available when they are needed most.

The document’s recommendations outline what studies and reports are required for changes to cell and gene therapy manufacturing.

The new drug may help vulnerable children resist RSV in the coming fall and winter season.